eXoZymes

@eXoZymes Inc. has validated its cell-free biomanufacturing platform through a successful pilot-scale run with Cayman Chemical, producing over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity. This milestone not only demonstrates the technology's scalability but also achieves a remarkable 99% feedstock conversion rate, paving the way for potential commercialization and collaboration opportunities in nutraceuticals and novel medicines. synbiobeta.com/read/successfu… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Mark your calendars: $EXOZ investor update: 4Q + full year 2025 - on - Tuesday, March 31, 2026 at 5:30 PM Eastern Time. CEO of @eXoZymes, Michael @Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. You can pre-register for the webinar HERE: na2.hubs.ly/H04vNGP0 #enzymes #exozymes #nutraceuticals #cellfree #exozyme #biosolution #biomanufacturing #enzyme

eXoZymes' Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman Chemical @CaymanChemical advanced the protocol from a 1-L setup to a 100-L pilot run, operating the reaction and analysis independently #biomanufacturing #AI #drugdevelopment hubs.li/Q047yD3s0

Interview: @CaymanChemical validates @eXoZymes' technology and scalability Director of Catalog Chemistry Production at Cayman Chemical, Patrick Westcott, states: “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!” See the full interview here: na2.hubs.ly/H04mBkv0 $EXOZ #exozymes #exozyme #enzymes #enzyme #biomanufacturing #CaymanChemical #chemicals #biocatalysis #pilotscale #NCT #Ntranscaffeoyltyramine

eXoZymes (@eXoZymes) (Nasdaq: EXOZ) announced that Chief Commercial Officer Damien Perriman will present at the MISTA Symposium Healthspan event in San Francisco on March 18, 2026. eXoZymes is a B2i Digital (@b2idigital) Featured Company. See their full profile at b2idigital.com/exozymes-1. Perriman’s presentation will focus on scaling production of NCT, a plant-derived molecule with potential applications in both nutraceutical and pharmaceutical markets. NCT has attracted attention for its possible role in metabolic health, specifically how the body converts fuel into energy. Its rarity in nature has historically limited commercial development, but eXoZymes is working to change that through its exozyme platform, which uses AI-designed enzyme cascades operating outside living cells to enable scalable production. The MISTA Symposium Healthspan event brings together leaders from the food, nutrition, and health industries to explore how scientific advances can support healthier aging and metabolic resilience. Perriman commented: “When it comes to health, a lot of people feel frustrated because they’re trying - but nothing seems to work. They feel trapped between conflicting advice and solutions that are difficult to sustain. But now there’s hope - what makes NCT so exciting is that it focuses on the underlying problem: how the body converts fuel into energy. By addressing that fundamental process, we believe it could represent a meaningful new approach to metabolic health. We’re excited to share how advances in cell-free enzyme engineering are making it possible to bring this rare natural compound into scalable production and explore its potential across nutrition and medicine.” Read the full press release here: exozymes.com/blog/2026-mist… eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit exozymes.com. For investor inquiries, visit exozymes.com/investor. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of b2idigital.com/disclaimer.

In a recent episode of The Big Skinny - the SportsCenter of Financial News - @FoxBusiness contributor, @LouBasenese, stated: "@eXoZymes is a new way to create chemicals. It's like the @BASF of the 2026 [...] We don't make a lot of the products you buy. We make a lot of the products you buy better." Full episode available here: na2.hubs.ly/H03YqQD0 #exozymes #exozyme #enzymes #enzyme #biomanufacturing $EXOZ

“As outlined late last year, we have a tighter strategic focus on medicines and pharmaceutical-adjacent opportunities. With this launch, our external presentation now fully aligns with that direction. What investors hear from us regarding focus and priorities is now clearly reflected in how we present ourselves." - said Lasse H. Görlitz (@goerlitz), VP of Comms & IR at @eXoZymes (Nasdaq: $EXOZ), and continues, "The website will continue to evolve and add new features as well as new content as we progress towards future commercial milestones."

We're proud to anounce the launch of a redesigned corporate website and updated visual identity, reflecting our refined strategic focus on pharmaceutical and nutraceutical markets. Michael @Heltzen, CEO of @eXoZymes, states, “Our strategy is built around disciplined focus and platform leverage. We are concentrating our technology and business development efforts on highly valuable pharmaceutical and nutraceutical markets - segments that we believe are defined by no or low current access, attractive margin profiles, strong intellectual property protection, meaningful technical barriers to entry, and long-term commercial durability.” Full story here: na2.hubs.ly/H03zZTQ0 #exozymes #exozyme #enzymes #enzyme #biomanufacturing

As part of @Nasdaq's 'Amplify Spotlight' series, CEO of eXoZymes, Michael Heltzen (@heltzen), recently sat down with Michael B. Spector (@michaelbspector) from Nasdaq for a in-depth interview. Heltzen states: "That's how we can run these simulations much much faster and much cheaper than anyone else and therefore it allows us to to brute force evolution." Full interview available here: exozymes.com/blog/nasdaq-in… $EXOZ @NasdaqExchange #exozymes #exozyme #enzymes #enzyme

Team Lead of Biosolutions and R&D Services, Adrian Brückner (@AdrianBrueckner), PhD, adds, “What stood out to me in this run was not just the impressive final performance numbers, but how straightforward and reliable the process proved to be under real operating conditions. The reaction was executed using a written, step-by-step protocol by an external team, and it performed exactly as intended. From a process perspective, that level of consistency - combined with high recovery, isolated yield, and purity at this scale - gives us confidence that the system is not only scalable, but operationally robust and well suited for continued manufacturing development. Importantly, this successful production of more than half a kilogram of pharma-grade purity NCT means that we’re now ready to share formulation samples with relevant partners.” Full story here: na2.hubs.ly/H03mqLX0 NCT formulation can be shipped to partners: With isolated high-purity NCT now produced at pilot scale, we're actively engaging with partners interested in formulation development, product validation, and application-specific testing. The availability of high-purity material enables partners to move beyond feasibility studies and into hands-on evaluation under relevant conditions. Companies seeking to explore potential use cases, assess performance, or initiate collaborative development discussions are invited to contact eXoZymes to request samples and discuss next steps, right here: na2.hubs.ly/H03mtgd0 #exozymes #exozyme #enzymes #enzyme #biomanufacturing #NCT #cellfree #pharmagrade $EXOZ

@RugbyFan2021 Generally speaking: If you look at our presentations, there is an expected increase in gross margins over time.

@eXoZymes Another question that I understand you probably can’t comment on. But with the conversion increasing at scale you would think this only increases the gross margins on what as per last quarterly presentation was already an attractive high gross margin opportunity.

Advancing commercial readiness with profound production metrics on initial NCT pilot run: The pilot run achieved approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity at 100L scale. Co-founder of @eXoZymes and VP of Development, Paul Opgenorth (@popgenorth), PhD, states: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend.” Full story here: na2.hubs.ly/H03l_W90 #exozymes #enzymes #nutraceuticals #exozyme #biomanufacturing #enzyme

Los Angeles-based @eXoZymes Inc. (NASDAQ: EXOZ), a pioneer of AI-enhanced enzymes that transform sustainable feedstock into nutraceuticals and new medicines, reported detailed downstream performance results from its recently completed 100-liter pilot production run of N-trans-caffeoyltyramine (NCT). eXoZymes Inc. is a @b2idigital Featured Company. See their full profile at b2idigital.com/exozymes-1. The company reports that the pilot run achieved approximately 99% reaction conversion, 91% process recovery, and a 90% isolated yield, resulting in 535 grams of isolated NCT at 99.6% pharma-grade purity. The production was executed by external partner Cayman Chemical, marking the first time the exozyme-based biomanufacturing process has been run end-to-end by an external partner, demonstrating protocol transferability and operational robustness. Co-founder of eXoZymes and VP of Development, Paul Opgenorth, PhD, noted: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend. At very small laboratory scale, where cell-free reactions are usually developed and optimized, performance can actually be the weakest. It improves at the one-liter scale, and this scaled run at 100 liters further reinforces that the system benefits from operating at larger volumes. Seeing that behavior carry through to high recovery, isolated yield, and pharma-grade purity supports that exozymes represent a fundamentally different and more scalable biomanufacturing paradigm compared to existing approaches.” Read the full news release at: exozymes.com/blog/nct-pilot… eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. To learn more about eXoZymes Inc., visit exozymes.com. For investor inquiries, visit exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of b2idigital.com/disclaimer.

@eXoZymes NCT system performs even better at scale! Before the recent 100L pilot plant scaling, @eXoZymes produced 4 grams in the lab from an assumed 1L bioreactor. Now at 100L, they are achieving 535 grams! 99% Reaction Conversion 90% Isolated Yield 99.6% Pharma-grade Purity

@RugbyFan2021 @LouBasenese 😂

@eXoZymes @LouBasenese Just saw this. I can’t claim the credit but found it amusing.

@RugbyFan2021 @LouBasenese Thanks! And yes, would be great with another round with Lou!

@eXoZymes Amazing!!! Great work team! @LouBasenese some more podcast content here!

Our Capital Markets Advisor, Sanjeev Srivastava, was interviewed by @maxinehoovernyc from The Beryl Consulting Group at the @BerylElites Investment Conference in New York City: "Biomanufacturing is going through its ChatGPT moment. The reason for that is, that eXoZymes has the technology to make enzymes function outside of cells. I know that sounds a bit technical, but what that means is that many medicines, nutraceuticals, and other chemicals, can be made much more cost-effective and in a way that nature could not provide - it was impossible to get these products. This is a very exciting time for the industry!" Interview available here: na2.hubs.ly/H02Xn320 #exozymes #exozyme #enzymes #enzyme #biomanufacturing #cellfree #AI #ML #artificialintelligence #chatgpt

Our CEO, Michael @Heltzen, was interviewed by @maxinehoovernyc from The Beryl Consulting Group at the @BerylElites’ Investment Conference in New York City: "Artificial evolution is our way of describing how we can brute force evolution. With the development of AI algorithms over the last couple of years, we have gained access to the capability of foreseeing what a change in the DNA code means to the structure and function of enzymes. So we can basically start designing how the chemical reactions are happening. That means we're expanding the chemical space of what's possible to build, like natural products and drug candidates that were considered impossible to build before." Interview available here: na2.hubs.ly/H02Xmfn0 #exozymes #exozyme #enzymes #enzyme #biomanufacturing #cellfree #AI #ML #artificialintelligence #artificialevolution #directedevolution #evolution